Cellectis S.A. (NASDAQ:CLLS)’s share price rose 20.6% during mid-day trading on Tuesday . The company traded as high as $32.46 and last traded at $25.55. Approximately 3,105,543 shares were traded during mid-day trading, an increase of 2,531% from the average daily volume of 118,032 shares. The stock had previously closed at $32.18.

CLLS has been the topic of a number of analyst reports. Zacks Investment Research cut shares of Cellectis from a “buy” rating to a “hold” rating in a research note on Thursday, August 10th. Jefferies Group LLC set a $47.00 target price on shares of Cellectis and gave the company a “buy” rating in a research note on Friday, August 25th. Oppenheimer Holdings, Inc. set a $40.00 target price on shares of Cellectis and gave the company a “buy” rating in a research note on Wednesday, May 10th. BidaskClub upgraded shares of Cellectis from a “strong sell” rating to a “sell” rating in a research note on Wednesday, August 23rd. Finally, Wells Fargo & Company restated an “outperform” rating and set a $40.00 target price (up previously from $33.00) on shares of Cellectis in a research note on Tuesday. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the company’s stock. Cellectis presently has an average rating of “Buy” and a consensus price target of $41.50.

The stock’s 50-day moving average is $25.11 and its 200-day moving average is $24.03. The company’s market cap is $920.22 million.

Hedge funds have recently modified their holdings of the company. Sphera Funds Management LTD. grew its stake in shares of Cellectis by 27.6% during the second quarter. Sphera Funds Management LTD. now owns 203,764 shares of the biotechnology company’s stock worth $5,261,000 after acquiring an additional 44,100 shares during the last quarter. Trexquant Investment LP purchased a new stake in shares of Cellectis during the first quarter worth about $214,000. Vident Investment Advisory LLC grew its stake in shares of Cellectis by 20.0% during the first quarter. Vident Investment Advisory LLC now owns 50,994 shares of the biotechnology company’s stock worth $1,224,000 after acquiring an additional 8,496 shares during the last quarter. Eqis Capital Management Inc. grew its stake in shares of Cellectis by 27.2% during the second quarter. Eqis Capital Management Inc. now owns 10,687 shares of the biotechnology company’s stock worth $276,000 after acquiring an additional 2,287 shares during the last quarter. Finally, Williams Jones & Associates LLC purchased a new stake in shares of Cellectis during the second quarter worth about $244,000. Institutional investors and hedge funds own 14.85% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was originally reported by Daily Political and is owned by of Daily Political. If you are viewing this news story on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The legal version of this news story can be viewed at https://www.dailypolitical.com/2017/09/05/cellectis-s-a-clls-stock-price-up-20-6.html.

About Cellectis

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.